Our study found that several biomarkers, such as CHI3L1, IL-18, IL-36α, VCAM-1, MCP-1, CCL18, and PLR, showed promising potential in distinguishing RA from RA-ILD. This evidence concerns the gene CCL2 and interstitial lung disease.